drugset
Drugs / Coronavirus-2-specific T cells
last change Dec 2022 re-read 3 minutes ago

Coronavirus-2-specific T cells

also known as Coronavirus-specific T cells · SARS-CoV-2 specific T-cells · SARS-CoV-2-specific T Lymphocytes
Developed for
COVID-19
Investigated by
General Hospital Of Thessaloniki Ippokratio · George Papanicolaou Hospital

Trials 1

today NCT05447013 · Ph 1/2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05447013 Jun 2021 → Dec 2022 COVID-19 George Papanicolaou Hospital Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Coronavirus-2-specific T cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT05447013 ↗
Known as Coronavirus-specific T cells “Standard of care (SOC) and Coronavirus-specific T cells (CoV-2-STs)” NCT05447013 ↗
Known as SARS-CoV-2 specific T-cells “bank with GMP-compliant generated SARS-CoV-2 specific T-cells (CoV-2-STs)” NCT05447013 ↗
Known as SARS-CoV-2-specific T Lymphocytes “Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients” NCT05447013 ↗